Taurocholic acid - Satiogen Pharmaceuticals

Drug Profile

Taurocholic acid - Satiogen Pharmaceuticals

Alternative Names: sodium taurocholate - Satiogen Pharmaceuticals; taurocholate - Satiogen Pharmaceuticals

Latest Information Update: 16 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Satiogen Pharmaceuticals
  • Class Antihyperglycaemics; Bile acids and salts; Cholic acids; Obesity therapies; Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Obesity; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 28 May 2014 Taurocholic acid is still in phase I/II trials for Type-2 diabetes mellitus and Obesity in United Arab Emirates
  • 02 May 2014 Taurocholic acid - Satiogen Pharmaceuticals is available for licensing for Type-II diabetes mellitus and Obesity (excluding USA) as of 02 May 2014. www.satiogen.com
  • 03 May 2011 Satiogen Pharmaceuticals completes enrolment in its phase I trial in healthy volunteers in Australia (ACTRN12611000071921)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top